1



                                  UNITED STATES
                       SECURITIES AND EXCHANGE COMMISSION
                              Washington, DC 20549

                                   FORM 10-QSB

(Mark One)

X    QUARTERLY  REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES  EXCHANGE ACT
     OF 1934

                For the quarterly period ended September 30, 2003

     TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT
     OF 1934

     For the transition period from __________ to ____________

Commission File Number 2-93277-D

                          MEDIZONE INTERNATIONAL, INC.
        (Exact name of small business issuer as specified in its charter)

Nevada                                                87-0412648
(State or other jurisdiction               (IRS Employer Identification No.)
of incorporation or organization)



              144 Buena Vista P.O. Box 742 Stinson Beach, CA 94970
                    (Address of principal executive offices)

                                 (415) 868-0300
                           (Issuer's telephone number)



At November 10, 2003, there were 158,970,387 shares of the issuer's common stock
issued and outstanding.

Transitional Small Business Disclosure Format (Check one): Yes [  ] No [X]



<PAGE>


                          MEDIZONE INTERNATIONAL, INC.
                                   FORM 10-QSB


                                      INDEX
                               September 30, 2003


<TABLE>
<CAPTION>
                                                                                   Page
                                                                                   Number

Part I -- Financial Information


Item 1 -- Financial Statements


<S>                                                                                       <C>
           Consolidated Balance Sheets:
         September 30, 2003 (Unaudited) and December 31, 2002..............................1

            Consolidated Statements of Operations (Unaudited):
         For the Three Months and Nine Months Ended September 30, 2003 and 2002............2

        Consolidated Statements of Cash Flow (Unaudited)
         For the Nine Months Ended September 30, 2003 and 2002.............................3

             Notes to the Consolidated Financial Statements................................5

Item 2--Management's Discussion and Analysis or Plan of Operation..........................9

Item 3-- Controls and Procedures..........................................................10


Part II -- Other Information


Item 6-- Exhibits and Reports on Form 8-K.................................................11
</TABLE>





<PAGE>


                         PART I -- FINANCIAL INFORMATION

Item 1.  Financial Statements

                  MEDIZONE INTERNATIONAL, INC. AND SUBSIDIARIES
                          (A Development Stage Company)
                           Consolidated Balance Sheets



<TABLE>
<CAPTION>
                        ASSETS
                                                                                    September 30,       December 31,
                                                                                        2003                   2002
                                                                                 --------------------   --------------------
                                                                                     (Unaudited)
CURRENT ASSETS

<S>                                                                              <C>                    <C>
      Cash                                                                       $                77    $                72
                                                                                 --------------------   --------------------

          Total Current Assets                                                                    77                     72
                                                                                 --------------------   --------------------

PROPERTY AND EQUIPMENT (Net)                                                                   2,174                  5,475
                                                                                 --------------------   --------------------

OTHER ASSETS

      Receivable from affiliate, net                                                               -                      -
                                                                                 --------------------   --------------------

          Total Other Assets                                                                       -                      -
                                                                                 --------------------   --------------------

          TOTAL ASSETS                                                           $             2,251    $             5,547
                                                                                 ====================   ====================

               LIABILITIES AND STOCKHOLDERS' EQUITY (DEFICIT)

CURRENT LIABILITIES

      Accounts payable                                                           $           676,384    $           598,735
      Advances from shareholders                                                               1,200                  5,057
      Accrued expenses                                                                     1,241,982                980,444
      Notes payable                                                                          280,491                303,491
                                                                                 --------------------   --------------------

          Total Current Liabilities                                                        2,200,057              1,887,727
                                                                                 --------------------   --------------------

          Total Liabilities                                                                2,200,057              1,887,727
                                                                                 --------------------   --------------------

STOCKHOLDERS' EQUITY (DEFICIT)

      Common stock, 250,000,000 shares authorized of $0.001
       par value, 158,970,387 and 157,745,387 shares issued
       and outstanding, respectively                                                         158,970                157,745
      Additional paid-in capital                                                          15,753,575             15,693,550
      Deficit accumulated during the development stage                                   (18,110,351)           (17,733,475)
                                                                                 --------------------   --------------------

          Total Stockholders' Equity (Deficit)                                            (2,197,806)            (1,882,180)
                                                                                 --------------------   --------------------

          TOTAL LIABILITIES AND STOCKHOLDERS'
           EQUITY (DEFICIT)                                                      $             2,251    $             5,547
                                                                                 ====================   ====================
</TABLE>




              The accompanying notes are an integral part of these
                       consolidated financial statements.

                                       1
<PAGE>


                  MEDIZONE INTERNATIONAL, INC. AND SUBSIDIARIES
                          (A Development Stage Company)
                      Consolidated Statements of Operations
                                   (Unaudited)

<TABLE>
<CAPTION>
                                                                                                               From Inception
                                                       For the                          For the                on January 31,
                                                    Three Months Ended               Nine Months Ended          1986 Through
                                                      September 30,                    September 30,            September 30,
                                             -------------------------------- --------------------------------
                                                  2003             2002            2003             2002            2003
                                             ---------------- --------------- ---------------- --------------- ----------------

<S>                                          <C>              <C>             <C>              <C>             <C>
REVENUES                                     $             -  $            -  $             -  $            -  $       133,349
                                             ---------------- --------------- ---------------- --------------- ----------------

EXPENSES

     Cost of sales                                         -               -                -               -          103,790
     Research and development                              -               -                -          40,602        2,685,788
     General and administrative                      118,751         174,770          354,100         411,690       13,709,554
     Expense on extension of warrants                      -               -                -               -        1,866,857
     Bad debt expense                                      -               -                -               -           48,947
     Depreciation and amortization                       962           1,188            3,301           3,563           45,822
                                             ---------------- --------------- ---------------- --------------- ----------------

        Total Expenses                               119,713         175,958          357,401         455,855       18,460,758
                                             ---------------- --------------- ---------------- --------------- ----------------

        Loss from Operations                        (119,713)       (175,958)        (357,401)       (455,855)     (18,327,409)
                                             ---------------- --------------- ---------------- --------------- ----------------

OTHER INCOME (EXPENSES)

     Minority interest in loss                             -               -                -               -           26,091
     Other income                                          -               -                -               -           19,780
     Gain on sale of subsidiary                            -               -                -               -          208,417
     Interest expense                                 (7,647)         (5,914)         (19,475)        (17,742)        (931,968)
                                             ---------------- --------------- ---------------- --------------- ----------------

        Total Other Income (Expenses)                 (7,647)         (5,914)         (19,475)        (17,742)        (677,680)
                                             ---------------- --------------- ---------------- --------------- ----------------

LOSS BEFORE EXTRAORDINARY ITEMS                     (127,360)       (181,872)        (376,876)       (473,597)     (19,005,089)
                                             ---------------- --------------- ---------------- --------------- ----------------

EXTRAORDINARY ITEMS

     Lawsuit settlement                                    -               -                -               -          415,000
     Debt forgiveness                                      -               -                -               -          479,738
                                             ---------------- --------------- ---------------- --------------- ----------------

        Total Extraordinary Items                          -               -                -               -          894,738
                                             ---------------- --------------- ---------------- --------------- ----------------

NET LOSS                                     $      (127,360) $     (181,872) $      (376,876) $     (473,597) $   (18,110,351)
                                             ================ =============== ================ =============== ================

BASIC LOSS PER SHARE                         $         (0.00) $        (0.00) $         (0.00) $        (0.00)
                                             ================ =============== ================ ===============

WEIGHTED AVERAGE NUMBER OF
 COMMON SHARES OUTSTANDING                       158,970,387      157,505,387     158,698,629      156,680,267
                                             ================ =============== ================ ===============
</TABLE>



              The accompanying notes are an integral part of these
                       consolidated financial statements.

                                       2
<PAGE>


                  MEDIZONE INTERNATIONAL, INC. AND SUBSIDIARIES
                          (A Development Stage Company)
                      Consolidated Statements of Cash Flows
                                   (Unaudited)

<TABLE>
<CAPTION>
                                                                                                       From Inception
                                                                                                       on January 31,
                                                                    For the Nine Months Ended           1986 Through
                                                                 September 30,                          September 30,
                                                             ---------------------------------------
                                                                     2003                 2002              2003
                                                             ---------------------   --------------- --------------------

CASH FLOWS FROM OPERATING ACTIVITIES:

<S>                                                          <C>                     <C>             <C>
Net loss                                                     $           (376,876)   $     (473,597) $       (18,110,351)
Adjustments to reconcile net loss to net cash
 used in operating activities:
     Depreciation and amortization                                          3,301             3,563               45,822
     Stock issued for services                                              5,000            71,000            3,091,916
     Expense for extension of warrants below
      market value                                                              -                 -            1,866,857
     Bad debt expense                                                           -                 -               48,947
     Minority interest in loss                                                  -                 -              (26,091)
     Loss on disposal of assets                                                 -                 -              693,752
     Gain on settlement of debt                                                 -                 -             (188,510)
     Gain on lawsuit settlement                                                 -                 -             (415,000)
Changes in assets and liabilities:
     (Increase) in prepaid expenses and deposits                                -                 -              (48,947)
     Increase in accounts payable                                          77,649            86,885            1,070,914
     Increase in accrued expenses                                         261,538           182,679            1,665,004
                                                             ---------------------   --------------- --------------------

         Net Cash Used by Operating Activities                            (29,388)         (129,470)         (10,305,687)
                                                             ---------------------   --------------- --------------------

CASH FLOWS FROM INVESTING ACTIVITIES:

     Organization costs                                                         -                 -               (8,904)
     Purchase of fixed assets                                                   -                 -              (39,090)
                                                             ---------------------   --------------- --------------------

         Net Cash Used by Investing Activities                                  -                 -              (47,994)
                                                             ---------------------   --------------- --------------------

CASH FLOWS FROM FINANCING ACTIVITIES:

     Bank overdraft                                                             -                (8)                   -
     Proceeds from lawsuit settlement                                           -                 -              415,000
     Principal payments on notes payable                                        -                 -             (192,774)
     Cash received from notes payable                                           -                 -            1,129,518
     Advances from shareholders                                             1,200             5,337               11,544
     Payment on shareholder advances                                       (5,057)                -               (5,057)
     Capital contributions                                                      -                 -              421,847
     Stock issuance costs                                                       -                 -             (105,312)
     Increase in minority interest                                              -                 -               14,470
     Issuance of common stock for cash                                     33,250           125,000            8,664,522
                                                             ---------------------   --------------- --------------------

         Net Cash Provided by Financing Activities                         29,393           130,329           10,353,758
                                                             ---------------------   --------------- --------------------

NET INCREASE (DECREASE) IN CASH                                                 5               859                   77

CASH AT BEGINNING OF PERIOD                                                    72                 -                    -
                                                             ---------------------   --------------- --------------------

CASH AT END OF PERIOD                                        $                 77    $          859  $                77
                                                             =====================   =============== ====================
</TABLE>


              The accompanying notes are an integral part of these
                       consolidated financial statements.

                                       3
<PAGE>


                  MEDIZONE INTERNATIONAL, INC. AND SUBSIDIARIES
                          (A Development Stage Company)
                Consolidated Statements of Cash Flows (Continued)
                                   (Unaudited)


<TABLE>
<CAPTION>
                                                                                                       From Inception
                                                                                                       on January 31,
                                                                    For the Nine Months Ended           1986 Through
                                                                 September 30,                          September 30,
                                                             ---------------------------------------
                                                                     2003                 2002              2003
                                                             ---------------------   --------------- --------------------

SUPPLEMENTAL CASH FLOW INFORMATION

CASH PAID FOR:

<S>                                                          <C>                     <C>             <C>
         Interest                                            $                  -    $            -  $            26,483
         Income taxes                                        $                  -    $            -  $                 -

NON-CASH FINANCING ACTIVITIES

         Stock issued for services                           $              5,000    $       71,000  $         3,091,916
         Stock issued for conversion of debt                 $             23,000    $       44,737  $         4,139,230
         Stock issued for license agreement and patent       $                  -    $            -  $           693,752
</TABLE>



              The accompanying notes are an integral part of these
                       consolidated financial statements.

                                       4
<PAGE>


                  MEDIZONE INTERNATIONAL, INC. AND SUBSIDIARIES
                          (A Development Stage Company)
                 Notes to the Consolidated Financial Statements
                    September 30, 2003 and December 31, 2002


NOTE 1 -      BASIS OF PRESENTATION

              The financial information included herein is unaudited and has
              been prepared consistent with generally accepted accounting
              principles for interim financial information and with the
              instructions to Form 10-QSB and Item 310(b) of Regulation S-B.
              Accordingly, these financial statements do not include all
              information and footnotes required by generally accepted
              accounting principles for complete financial statements. These
              statements should be read in conjunction with the audited
              financial statements and notes thereto included in the Company's
              annual report on Form 10-KSB for the year ended December 31, 2002.
              In the opinion of management, these financial statements contain
              all adjustments (consisting solely of normal recurring
              adjustments) which are, in the opinion of management, necessary
              for a fair statement of results for the interim period presented.

The results of operations for the three months and nine months ended September
30, 2003 and 2002 are not necessarily indicative of the results to be expected
for the full year.

NOTE 2 -      LOSS PER SHARE

              Following is a reconciliation of the numerators of the basic and
              diluted loss per share for the three months and nine months ended
              September 30, 2003 and 2002:

<TABLE>
<CAPTION>
                                                                                               For the
                                                                                   Three Months Ended
                                                                                          September 30,
                                                                                    2003                2002
                                                                            ----------------- --------------------
<S>                                                                         <C>               <C>
              Net loss available to
               common shareholders                                          $       (127,360) $          (181,872)
                                                                            ================= ====================

              Weighted average shares                                             158,970,387         157,505,387
               Effect of dilutive securities                                                -                   -
                                                                            ------------------  ------------------

                                                                                  158,970,387         157,505,387
              Basic loss per share (based
               on weighted average
               shares)                                                      $           (0.00)  $           (0.00)
                                                                            ==================  ==================
</TABLE>


                                       5
<PAGE>


                  MEDIZONE INTERNATIONAL, INC. AND SUBSIDIARIES
                          (A Development Stage Company)
                 Notes to the Consolidated Financial Statements
                    September 30, 2003 and December 31, 2002


NOTE 2 -      LOSS PER SHARE (Continued)

<TABLE>
<CAPTION>
                                                                                            For the
                                                                                   Nine Months Ended
                                                                                          September 30,
                                                                                    2003                2002
                                                                            ----------------- ------------------
<S>                                                                         <C>               <C>
              Net loss available to
               common shareholders                                          $       (376,876) $        (473,597)
                                                                            ================= ==================

              Weighted average shares                                            158,698,629        156,680,267
               Effect of dilutive securities                                               -                  -
                                                                            ----------------- ------------------

                                                                                 158,698,629        156,680,267
              Basic loss per share (based
               on weighted average
               shares)                                                      $          (0.00) $           (0.00)
                                                                            ================= ==================
</TABLE>

              Common stock equivalents, consisting of warrants and options, have
              not been included in the calculation as their effect is
              antidilutive for the periods presented.

NOTE 3 -      GOING CONCERN

              The Company's consolidated financial statements are prepared using
              generally accepted accounting principles applicable to a going
              concern which contemplates the realization of assets and
              liquidation of liabilities in the normal course of business. The
              Company has incurred significant losses from its inception through
              September 30, 2003 which have resulted in an accumulated deficit
              of $18,110,351 at September 30, 2003. The Company does not have an
              established source of funds sufficient to cover its operating
              costs, has a working capital deficit of approximately $2,200,000,
              has relied exclusively on debt and equity financing, accordingly,
              there is substantial doubt about its ability to continue as a
              going concern.

              Continuation of the Company as a going concern is dependent upon
              obtaining additional capital, obtaining the requisite approvals
              from the FDA and/or the EU for the marketing of ozone-related
              products and equipment, and ultimately, upon the Company's
              attaining profitable operations. The Company will require a
              substantial amount of additional funds to complete the development
              of its products, to establish manufacturing facilities, to build a
              sales and marketing organization and to fund additional losses,
              which the Company expects to incur over the next several years. If
              the Company is unsuccessful in the next few months to raise
              necessary capital, it will be forced to cease operations.







                                       6

<PAGE>


                  MEDIZONE INTERNATIONAL, INC. AND SUBSIDIARIES
                          (A Development Stage Company)
                 Notes to the Consolidated Financial Statements
                    September 30, 2003 and December 31, 2002

NOTE 3 -  GOING CONCERN (Continued)

Because ozone-generation for the purposes of interfacing with blood and blood
products is regarded as a new drug delivery system, the Company is precluded
from selling or distributing its drug or the Medizone Technology in the United
States until after FDA approval has been granted. In order to obtain FDA
approval, the Company will be required to submit a New Drug Application ("NDA")
for review by the FDA and provide medical and scientific evidence sufficient to
demonstrate that the drug and the Medizone Technology has been successfully used
in pre-clinical studies followed by three phases of well-controlled clinical
studies using human volunteer subjects. The FDA will not grant an NDA unless it
contains sufficient medical evidence and data to permit a body of qualified and
experienced scientists to conclude that the new drug product is safe and
effective for its recommended and proposed medical uses. Historically, the FDA
has held a strong bias against treating humans with ozone, due largely to issues
of safety.

              In order to initiate the first phase (i.e., Phase I) of human
              clinical trials required as part of an NDA, an applicant must
              submit to the FDA an application for an Investigational New Drug
              Exemption ("IND"), which contains adequate information to satisfy
              the FDA that human clinical trials can be conducted without
              exposing the volunteer human subjects to an unreasonable risk of
              illness or injury. The Company submitted an IND application
              (assigned to the Company by its former president) to the FDA on
              October 6, 1985, and requested FDA approval to commence human
              clinical trials using ozone-oxygen to inactivate HIV. The FDA
              deemed the IND application to be incomplete, and required the
              Company to conduct additional animal studies prior to commencing a
              large animal study and human trials. In September 1994, after not
              receiving responses to requests for information from the Company,
              the FDA inactivated the Company's IND. The Company has no present
              plans to commence a large animal study, which would require, as a
              precursor, additional small animal and laboratory work.
              Accordingly, there can be no assurance that the Company's IND
              application will ever be reopened. Until an NDA had been granted
              to the Company, it may not distribute ozone-generating devices,
              except to researchers who agree to follow FDA guidelines, and
              provided the devices are labeled as "Investigational Devices."

              Because ozone has been used to treat humans in Europe for at least
              30 years, the EU is more accepting of human clinical trials of
              ozone therapies being conducted than is the United States.
              Accordingly, management believes that the Company should pursue
              the option of conducting human clinical trials in Europe or other
              domains outside of the United States, using stringent protocols
              designed to meet EU, FDA and MCI (United Kingdom) standards, with
              a view to utilizing the results of such a trial(s) in an effort to
              obtain EU, FDA and MCI approvals in the future and to market the
              product in certain countries of need outside of the United States
              accepting of those trial results on an accelerated basis. The
              Company estimates that 90% of its potential market is outside the
              United States.

              The management of the Company intends to seek additional funding
              which will be utilized to fund additional research and continue
              operations. The Company recognizes that, if it is unable to raise
              additional capital in the near future, it may find it necessary to
              substantially reduce or cease operations.



                                       7
<PAGE>


                  MEDIZONE INTERNATIONAL, INC. AND SUBSIDIARIES
                         ( A Development Stage Company)
                 Notes to the Consolidated Financial Statements
                    September 30, 2003 and December 31, 2002

NOTE 3 -      GOING CONCERN (Continued)

              The ability of the Company to continue as a going concern is
              dependent on its ability to successfully accomplish the plan
              described in the preceding paragraphs and eventually attain
              profitable operations. The consolidated financial statements do
              not include any adjustments relating to the recoverability and
              classification of asset carrying amounts or the amount and
              classification of liabilities that might result from the outcome
              of these uncertainties.

NOTE 4 -      STOCK TRANSACTIONS

              On January 1, 2003, the Company issued 460,000 shares of common
              stock at $0.05 per share in lieu of a note payable totaling
              $23,000.

              On March 25, 2003, the Company issued 400,000 shares of common
              stock at $0.05 per share for total proceeds of $20,000. The
              Company also granted the investor warrants to purchase 400,000
              shares of stock at $0.05 per share, exercisable over a two-year
              term. The market price of the common stock was $0.05 per share on
              the date of the issuance of the shares and grant of the warrants.

              On April 9, 2003, the Company issued 100,000 shares of common
              stock at $0.05 per share for total proceeds of $5,000. The Company
              also granted the investor warrants to purchase 100,000 shares of
              stock at $0.05 per share, exercisable over a two-year term. The
              market price of the common stock was $0.05 per share on the date
              of the issuance of the shares and grant of the warrants.

              On April 11, 2003, the Company issued 100,000 shares of common
              stock to an officer of the Company for services rendered valued at
              $0.05 per share for a total value of $5,000.

              On May 2, 2003, the Company issued 165,000 shares of common stock
              at $0.05 per share for total proceeds of $8,250. The Company also
              granted the investor warrants to purchase 165,000 shares of stock
              at $0.05 per share, exercisable over a two-year term. The market
              price of the common stock was $0.05 per share on the date of the
              issuance of the shares and grant of the warrants.

              On February 5, 2003, again on April 10, 2003 and July 10, 2003 and
              again on September 2, 2003, the Board of Directors of the Company
              agreed to extend the expiration date on certain outstanding
              warrants and options to purchase common stock as follows:
<TABLE>
<CAPTION>
                                                                                           New Dates
               Warrants/Options                       Exercise Price                      of Expiration
              ----------------------               ---------------------              ----------------------------
<S>                          <C>                   <C>                                <C>
                             750,000               $       0.20                       December 10, 2003
                             250,000               $       0.20                       December 10, 2003
                             400,000               $       0.15                       December 10, 2003
                             166,666               $       0.15                       December 10, 2003
                             555,555               $       0.18                       December 10, 2003
                             250,000               $       0.55                       December 10, 2003
</TABLE>

                                       8
<PAGE>


                  MEDIZONE INTERNATIONAL, INC. AND SUBSIDIARIES
                         ( A Development Stage Company)
                 Notes to the Consolidated Financial Statements
                    September 30, 2003 and December 31, 2002


NOTE 4 -      STOCK TRANSACTIONS (Continued)

              The following warrants were also outstanding as of September 30,
2003:

<TABLE>
<CAPTION>
                    Warrants                          Exercise Price                    Expiration Date
              ----------------------               ---------------------              ----------------------------
<S>                     <C>                        <C>                                <C>
                        1,000,000                  $       0.10                       March 25, 2004
                          250,000                  $       0.10                       May 22, 2004
                          400,000                  $       0.05                       March 25, 2005
                          100,000                  $       0.05                       April 9, 2005
                          165,000                  $       0.05                       May 2, 2005
</TABLE>

              The Company estimates the fair value of each stock award or
              expiration extension at the grant date or extension date by using
              the Black-Scholes option pricing model pursuant to FASB Statement
              123, "Accounting for Stock-Based Compensation". Under the
              provisions of SFAS 123, no additional expense was recorded at
              February 5, 2003, April 10, 2003, July 10, 2003 or September 2,
              2003 under the Black-Scholes option pricing model for these
              warrant and option extensions.

NOTE 5 -      COMMITMENTS AND CONTINGENCIES

              The Company is subject to certain claims and lawsuits arising in
              the normal course of business. In the opinion of management,
              uninsured losses, if any, resulting from the ultimate resolution
              of these matters will not have a material effect on the Company's
              financial position, results of operations, or cash flows.


NOTE 6 -      SUBSEQUENT EVENT

               Subsequent  to September  30, 2003,  the Company  issued  200,000
               shares of common  stock at $0.05 per share for total  proceeds of
               $10,000.  The  Company  also  granted  the  investor  warrants to
               purchase 200,000 shares of stock at $0.05 per share,  exercisable
               over a two-year  term.  The market  price of the common stock was
               $0.02 per share on the date of the  issuance  of the  shares  and
               grant of the warrants.



                                       9
<PAGE>



Item 2.  Management's Discussion and Analysis or Plan of Operation


         The following discussion and analysis of financial condition and plan
of operation should be read in conjunction with the unaudited Condensed
Consolidated Financial Statements and Notes thereto appearing elsewhere in this
Quarterly Report on Form 10-QSB.


         Medizone International, Inc., a Nevada corporation ("Medizone"),
organized in 1986, is a development stage company. To date our principal
business has been limited to (i) seeking regulatory approval of a precise
mixture of ozone and oxygen called MEDIZONE(R) (sometimes referred to in this
report as the "Drug"), and our process of inactivating lipid enveloped viruses
for the intended purpose of decontaminating blood and blood products and
assisting in the treatment of certain diseases; and (ii) developing or acquiring
the related technology and equipment for the medical application of our
products, including our drug production and delivery system (the "Medizone
Technology").


         The Drug is intended to be used as a therapeutic drug in humans to
inactivate certain viruses, and thereby afford a treatment for certain viral
diseases including Human Immunodeficiency Virus (the AIDS-related virus),
Hepatitis B, Hepatitis C, Epstein-Barr, herpes, and cytomegalovirus, and to
decontaminate blood and blood products.


Results of Operations


         From its inception in January 1986, Medizone International has been a
development stage company primarily engaged in research into the medical uses of
ozone. We have not generated, and cannot predict when or if we will generate
revenues or sufficient cash flow to fund our continuing operations. If we fail
to obtain additional funding, we will be forced to suspend or permanently cease
operations.


Three Months Ended September 30, 2003 and 2002


         There were no sales during the quarters ended September 30, 2003 or
2002. We made no expenditures for research and development during the quarters
ended September 30, 2003 and 2002. Since inception we have spent a total of
$2,685,788 for research and development.


         General and administrative expenses in the quarter ended September 30,
2003, were $118,751 compared to $174,770 during the same period in 2002. These
expenses include professional fees, payroll, insurance costs, and travel
expenses.


         Interest expense accrued during the three months ended September 30,
2003 and 2002, was $7,647 and $5,914, respectively.


Nine Months Ended September 30, 2003 and 2002


         There were no sales during the nine months ended September 30, 2003 or
2002. We incurred no research and development expense during the first nine
months of 2003, compared to expenditures of $40,602 during the nine months ended
September 30, 2002.


         General and administrative expenses during the nine months ended
September 30, 2003, were $354,100, compared to $411,690 during the first nine
months of 2002. The reduction in these expenses reflects the reduction in
employees and the limited business conducted by the company during the period as
efforts to obtain financing continued.


         Interest expense accrued during the nine months ended September 30,
2003 and 2002, was $19,475 and $17,742, respectively.


Liquidity and Capital Resources


         At September 30, 2003, we had a working capital deficiency of
$2,199,980 and stockholders' deficit of $2,197,806. At December 31, 2002, we had
a working capital deficiency of $1,887,655 and stockholders' deficit of

                                       10

<PAGE>

$1,882,180.


         Net cash used in operating activities during the nine months ended
September 30, 2003, was $29,388. Cash of $29,393 was provided during the nine
months ended September 30, 2003 primarily from the sale and issuance of common
stock and advances from shareholders. During the nine months ended September 30,
2002, there was net cash used in operating activities of $129,470. Cash of
$130,329 was provided in the first nine months of 2002 primarily by the sale and
issuance of common stock.


         The Company continues to require additional funding to enable it to
operate and to fund research necessary to make the appropriate regulatory
application and continue operations. We expect that these funds will be provided
by the sale of our securities. We recognize that if we are unable to raise
additional capital, we may find it necessary to substantially reduce or cease
operations.


Forward-Looking Statements and Risks Affecting the Company


         The statements contained in this Report on Form 10-QSB that are not
purely historical are "forward-looking statements" within the meaning of the
Private Securities Litigation Reform Act of 1995 and Section 21E of the
Securities Exchange Act. These statements regard our expectations, hopes,
beliefs, anticipations, commitments, intentions and strategies regarding the
future. They may be identified by the use of the words or phrases "believes,"
"expects," "anticipates," "should," "plans," "estimates," and "potential," among
others. Forward-looking statements include, but are not limited to, statements
contained in Management's Discussion and Analysis of or Plan of Operation
regarding our financial performance, revenue and expense levels in the future
and the sufficiency of existing assets to fund future operations and capital
spending needs. Actual results could differ materially from the anticipated
results or other expectations expressed in such forward-looking statements for
the reasons detailed in our Annual Report on Form 10-KSB for the year ended
December 31, 2002 under the headings "Description of Business" and "Risk
Factors." The fact that some of the risk factors may be the same or similar to
past reports filed with the Securities and Exchange Commission means only that
the risks are present in multiple periods. We believe that many of the risks
detailed here and in our SEC filings are part of doing business in the industry
in which we operate and compete and will likely be present in all periods
reported. The fact that certain risks are endemic to the industry does not
lessen their significance. The forward-looking statements contained in this
report are made as of the date of this Report and we assume no obligation to
update them or to update the reasons why actual results could differ from those
projected in such forward-looking statements. Among others, risks and
uncertainties that may affect our the business, financial condition,
performance, development, and results of operations include:

     o    Rigorous  government  scrutiny  and  regulation  of our  products  and
          planned products;

     o    Potential  effects of adverse  publicity  regarding  ozone and related
          technologies or industries;

     o    Failure to sustain or manage growth  including the failure to continue
          to develop new products; and

     o    The ability to obtain needed financing.


Item 3.    Controls and Procedures


         Within 90 days prior to the date of filing this report, an evaluation
was performed under the supervision and with the participation of the Company's
management, including the Chief Executive Officer and Chief Financial Officer,
of the effectiveness of the design and operation of the Company's disclosure
controls and procedures (as defined in Rule 13a-14(c) of the Exchange Act).
Based on and as of the time of such evaluation, the Company's management,
including the Chief Executive Officer and Chief Financial Officer, concluded
that the Company's disclosure controls and procedures were effective in timely
alerting them to material information relating to the Company (including its
consolidated subsidiaries) required to be included in the Company's reports
filed or submitted by it under the Exchange Act. There have been no significant
changes in the Company's internal controls or in other factors that could
significantly affect internal controls subsequent to the time of such
evaluation.

                                       11
<PAGE>

                          Part II -- Other Information


Item 6.  Exhibits and Reports on Form 8-K

(a)  Exhibits. The following exhibits are filed herewith pursuant to Rule 601 of
     Regulation S-B or are incorporated by reference to previous filings.

Exhibit #         Description

2    Agreement and Plan of Reorganization dated March 12, 1986 (2)

3.1  Articles of Incorporation of Company (2)

3.2  Bylaws (2)

3.3  Articles of Amendment to Company's Articles of Incorporation (3)

10.1 Loan  agreement  with Messrs.  McGrath and Watrous dated as of November 16,
     1992 (4)

10.2 Loan  Agreements  between  Medizone and John Kells,  George Handel and John
     Pealer, executed as of June 11, 1993 (and promissory notes) (4)

10.3 Agreement  for Sale and Purchase of Shares in Medizone New Zealand  Limited
     between Richard G. Solomon and Medizone International, Inc., dated June 22,
     1995 (5)

10.4 Shareholders'  Agreement  relating to Medizone New Zealand  Limited between
     and among Solwin  Investments  Limited,  Medizone  International,  Inc. and
     Medizone New Zealand Limited, dated June 22, 1995 (5)

10.5 Licensing  Agreement  between Medizone  International,  Inc. and MNZ, dated
     June 22, 1995 (5)

10.6 Managing Agent Agreement between Medizone International,  Inc. and Medizone
     New Zealand Limited, dated June 22, 1995 (5)

10.7 Funding commitment letter from Groundell Trust (6)

10.8 Letter re: change in certifying accountants (6)

31.1 Certification of President and Chief Executive Officer under Section 302 of
     Sarbanes-Oxley Act of 2002

31.2 Certification   of  Chief   Financial   Officer   under   Section   302  of
     Sarbanes-Oxley Act of 2002

32   Certification under Section 906 of Sarbanes-Oxley Act of 2002



(1)  Incorporated  by reference to annual report on form 10-K for the year ended
     December 31, 1998.

(2)  Incorporated   by  reference  to   registration   statement  on  Form  S-18
     (Registration No. 2-93277-D), effective May 14, 1985.

(3)  Incorporated  by  reference  to annual  report on Form 10-K for the  period
     ended December 31, 1986.

(4)  Incorporated  by  reference  to annual  report on Form 10-K for the  period
     ended December 31, 1992.

(5)  Incorporated  by  reference to current  report on Form 8-K,  dated June 22,
     1995.

(6)  Incorporated  by reference  to annual  report on Form 10-KSB for the period
     ended December 31, 2001.



                                       12
<PAGE>


                                   SIGNATURES

         In accordance with the requirements of the Exchange Act, the registrant
caused this report to be signed on its behalf by the undersigned, thereunto duly
authorized.

                          MEDIZONE INTERNATIONAL, INC.
                          (Registrant)


                          /s/ Edwin G. Marshall
                          -----------------------------------------------------
                          Edwin G. Marshall, Chairman and Chief Executive
                          Officer (Principal Executive Officer)


                          /s/ Steve M. Hanni
                          -----------------------------------------------------
                          Steve M. Hanni, Chief Financial Officer
                         (Principal Accounting Officer)


November 12, 2003